A Business at a Glance
0 of 1 daily views used (1 remaining). Sign up free for +5 more daily views (6 total), or try AAPL for a full preview.
STRATA Skin Sciences, Inc.
SSKN
$2K
Mkt Cap
$0.00
+100.00%
STRATA Skin Sciences, Inc. (SSKN) has a 5-year average return on invested capital (ROIC) of -26.5%. This is below average and may indicate limited pricing power.
STRATA Skin Sciences, Inc. (SSKN) has a market capitalization of $2K. It is classified as a small-cap stock.
STRATA Skin Sciences, Inc. (SSKN) does not currently pay a regular dividend.
STRATA Skin Sciences, Inc. (SSKN) operates in the Surgical & Medical Instruments & Apparatus industry, within the Healthcare sector.
STRATA Skin Sciences, Inc. (SSKN) reported annual revenue of $34 million in its most recent fiscal year, based on SEC EDGAR filings.
STRATA Skin Sciences, Inc. (SSKN) has a net profit margin of -30.1%. The company is currently unprofitable.
STRATA Skin Sciences, Inc. (SSKN) generated $-1 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
STRATA Skin Sciences, Inc. operates in the Surgical & Medical Instruments & Apparatus industry, Healthcare sector. Full business description from SEC filing not yet available.
| Metric | TTM | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | 31M | 34M | 33M | 36M | 30M | 23M |
| Net Income | -11M | -10M | -11M | -5.5M | -2.7M | -4.4M |
| EPS | $-2.61 | $-2.65 | $-3.10 | $-1.60 | $-0.78 | $-1.27 |
| Free Cash Flow | -3.5M | -1.4M | -5.5M | -4.7M | -2.1M | -63K |
| ROIC | -77.9% | -50.0% | -39.1% | -18.9% | -8.3% | -16.4% |
| Gross Margin | 58.2% | 56.9% | 55.3% | 60.2% | 66.2% | 61.2% |
| Debt/Equity | 11.65 | 3.06 | 1.19 | 0.34 | 0.29 | 0.10 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -9.4M | -9.3M | -8.6M | -4.6M | -4.4M | -4.1M |
| Operating Margin | -30.4% | -27.6% | -25.8% | -12.9% | -14.7% | -17.7% |
| ROE | -823.1% | -114.2% | -85.4% | -25.4% | -10.6% | -17.0% |
| Shares Outstanding | 6M | 4M | 3M | 3M | 3M | 3M |
| Metric | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||||
| Revenue | N/A | N/A | 18M | 31M | 32M | 30M | 32M | 23M | 30M | 36M | 33M | 34M | 31M |
| Gross Margin | N/A | N/A | 25.8% | 58.8% | 59.1% | 57.3% | 64.2% | 61.2% | 66.2% | 60.2% | 55.3% | 56.9% | 58.2% |
| R&D | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| SG&A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT | -24M | -17M | -16M | -3.6M | -1.8M | -3.4M | -3.0M | -4.1M | -4.4M | -4.6M | -8.6M | -9.3M | -9.4M |
| Op. Margin | N/A | N/A | -89.1% | -11.7% | -5.7% | -11.2% | -9.5% | -17.7% | -14.7% | -12.9% | -25.8% | -27.6% | -30.4% |
| Net Income | -26M | -16M | -28M | N/A | -8.9M | -2.9M | -3.8M | -4.4M | -2.7M | -5.5M | -11M | -10M | -11M |
| Net Margin | N/A | N/A | -150.9% | N/A | -27.9% | -9.7% | -12.0% | -19.1% | -9.0% | -15.3% | -32.5% | -30.1% | -34.9% |
| Non-Recurring | 1.0M | 16K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2.3M | 3.9M | 3.9M |
| Returns on Capital | |||||||||||||
| ROIC | N/M | N/M | -57.5% | N/A | -9.7% | -7.6% | -13.2% | -16.4% | -8.3% | -18.9% | -39.1% | -50.0% | -77.9% |
| ROE | -312.8% | -130.6% | -173.5% | N/A | -50.7% | -9.3% | -13.2% | -17.0% | -10.6% | -25.4% | -85.4% | -114.2% | -823.1% |
| ROA | -183.6% | -79.9% | -55.7% | N/A | -21.5% | -6.1% | -8.0% | -9.4% | -5.8% | -10.6% | -25.8% | -25.8% | -35.2% |
| Cash Flow | |||||||||||||
| Op. Cash Flow | -19M | -18M | -6.6M | 322K | 4.1M | 2.9M | 2.2M | 2.1M | 1.5M | -924K | -519K | 188K | -1.9M |
| Free Cash Flow | -25M | -18M | -6.6M | 322K | 4.1M | 2.9M | 2.1M | -63K | -2.1M | -4.7M | -5.5M | -1.4M | -3.5M |
| Owner Earnings | -23M | -20M | -12M | -6.2M | -2.4M | -3.4M | -3.5M | -3.1M | -3.9M | -7.7M | -7.4M | -5.2M | -7.2M |
| CapEx | 5.2M | 0 | 0 | 0 | 0 | 0 | 115K | 2.2M | 3.7M | 3.7M | 5.0M | 1.6M | 1.7M |
| Maint. CapEx | 2.4M | 1.8M | 4.1M | 6.4M | 6.3M | 5.4M | 4.5M | 3.6M | 3.7M | 5.3M | 5.6M | 5.0M | 5.0M |
| Growth CapEx | 2.7M | N/A | N/A | N/A | N/A | N/A | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| D&A | 2.4M | 1.8M | 4.1M | 6.4M | 6.3M | 5.4M | 4.5M | 3.6M | 3.7M | 5.3M | 5.6M | 5.0M | 5.0M |
| CapEx/OCF | N/A | N/A | N/A | N/A | N/A | N/A | 5.2% | 103.0% | 242.2% | N/A | N/A | 870.2% | 0.0% |
| Capital Allocation | |||||||||||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Buyback Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Stock-Based Comp | 1.3M | 413K | 1.8M | 113K | 186K | 904K | 1.2M | 1.6M | 1.6M | 1.5M | 1.3M | 427K | 427K |
| Debt Repayment | 6.4M | 0 | 0 | 0 | 1.4M | 3.0M | 7.6M | 0 | 500K | 0 | 0 | 0 | 0 |
| Balance Sheet | |||||||||||||
| Net Debt | -3.8M | -11M | 6.5M | 7.5M | 6.2M | -9.1M | -8.1M | -8.1M | -5.3M | 2.0M | 8.3M | 7.9M | 8.2M |
| Cash & Equiv. | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 7.1M |
| Long-Term Debt | 0 | 0 | 9.9M | 9.8M | 7.9M | 7.1M | 0 | 1.1M | 7.3M | 7.5M | 15M | 15M | 15M |
| Debt/Equity | 0.00 | 0.00 | 0.61 | 0.78 | 0.52 | 0.24 | 0.00 | 0.10 | 0.29 | 0.34 | 1.19 | 3.06 | 11.65 |
| Interest Coverage | -42.8 | -7.0 | -1.6 | -0.7 | -0.6 | -2.9 | -7.3 | -19.3 | -14.0 | -5.0 | -5.2 | -4.4 | -4.4 |
| Equity | 8.3M | 12M | 16M | 15M | 20M | 31M | 29M | 26M | 25M | 22M | 13M | 5.0M | 1.3M |
| Total Assets | 14M | 20M | 50M | 43M | 39M | 48M | 47M | 47M | 47M | 52M | 42M | 36M | 31M |
| Total Liabilities | 5.8M | 7.8M | 34M | 28M | 19M | 16M | 19M | 21M | 21M | 30M | 29M | 31M | 29M |
| Intangibles | 84K | N/A | 8.9M | 22M | 21M | 19M | 17M | 15M | 19M | 26M | 14M | 8.0M | 8.0M |
| Retained Earnings | -168M | -182M | -207M | -211M | -204M | -211M | -215M | -219M | -222M | -227M | -238M | -248M | -248M |
| Working Capital | 4.7M | 15M | 4.9M | 4.6M | 279K | 15M | 6.1M | 6.0M | 7.2M | 1.6M | 3.4M | 2.0M | 2.0M |
| Current Assets | 10M | 17M | 12M | 11M | 11M | 23M | 24M | 25M | 20M | 15M | 16M | 17M | 17M |
| Current Liabilities | 5.7M | 2.2M | 7.1M | 6.1M | 10M | 8.6M | 17M | 19M | 13M | 13M | 12M | 15M | 15M |
| Per Share Data | |||||||||||||
| EPS | -302.50 | -151.50 | -163.50 | -37.70 | -32.60 | -1.50 | -1.10 | -1.27 | -0.78 | -1.60 | -3.10 | -2.65 | -2.61 |
| Owner EPS | -269.92 | -188.17 | -72.49 | -14.06 | -0.72 | -1.76 | -1.01 | -0.90 | -1.11 | -2.22 | -2.11 | -1.37 | -1.23 |
| Book Value | 96.71 | 116.01 | 94.24 | 33.61 | 6.04 | 16.11 | 8.32 | 7.46 | 7.29 | 6.29 | 3.63 | 1.31 | 0.22 |
| Cash Flow/Share | -226.32 | -167.35 | -38.49 | 0.74 | 1.26 | 1.49 | 0.65 | 0.60 | 0.43 | -0.27 | -0.15 | 0.05 | -0.99 |
| Dividends/Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.00 |
| Shares Out. | 0.1M | 0.1M | 0.2M | 0.4M | 3.3M | 1.9M | 3.4M | 3.5M | 3.5M | 3.5M | 3.5M | 3.8M | 5.9M |
| Valuation | |||||||||||||
| P/E Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -0.0 |
| P/FCF | N/A | N/A | N/A | 32.0 | 9.9 | 19.1 | 34.9 | N/A | N/A | N/A | N/A | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price/Book | 3.4 | 0.6 | 0.6 | 0.7 | 2.1 | 1.8 | 2.6 | 2.1 | 1.9 | 1.3 | 1.5 | 2.3 | 0.0 |
| Price/Sales | N/A | N/A | 0.7 | 0.5 | 2.3 | 1.3 | 2.8 | 2.1 | 1.9 | 1.1 | 0.9 | 0.4 | 0.0 |
| FCF Yield | -88.2% | -259.5% | -68.7% | 3.1% | 10.1% | 5.2% | 2.9% | -0.1% | -4.4% | -16.8% | -28.8% | -12.8% | -149111.8% |
| Market Cap | 28M | 6.8M | 9.6M | 10M | 41M | 55M | 74M | 55M | 49M | 28M | 19M | 11M | 2K |
| Avg. Price | 516.55 | 195.09 | 73.57 | 37.57 | 22.19 | 20.67 | 25.37 | 14.19 | 16.38 | 11.44 | 8.19 | 3.84 | 0.00 |
| Year-End Price | 325.00 | 64.50 | 56.00 | 23.50 | 12.50 | 28.50 | 21.40 | 15.70 | 14.00 | 8.00 | 5.50 | 2.97 | 0.00 |
STRATA Skin Sciences, Inc. passes 2 of 9 quality checks, indicating weak fundamentals.
The company's 5-year average gross margin is 60.0%. At current prices, the estimated annualized return to fair value is -36.0%.
STRATA Skin Sciences, Inc. (SSKN) has a debt-to-equity ratio of 3.06. This indicates higher leverage, which may increase financial risk.
STRATA Skin Sciences, Inc. (SSKN) reported earnings per share (EPS) of $-2.65 in its most recent fiscal year.
STRATA Skin Sciences, Inc. (SSKN) has a return on equity (ROE) of -114.2%. A negative ROE may indicate losses or negative equity.
STRATA Skin Sciences, Inc. (SSKN) has a 5-year average gross margin of 60.0%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 13 years of financial data for STRATA Skin Sciences, Inc. (SSKN), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
STRATA Skin Sciences, Inc. (SSKN) has a book value per share of $1.31, based on its most recent annual SEC filing.